CN114574526B - Construction method of RPSA gene pig-derived mouse model - Google Patents
Construction method of RPSA gene pig-derived mouse model Download PDFInfo
- Publication number
- CN114574526B CN114574526B CN202210005243.9A CN202210005243A CN114574526B CN 114574526 B CN114574526 B CN 114574526B CN 202210005243 A CN202210005243 A CN 202210005243A CN 114574526 B CN114574526 B CN 114574526B
- Authority
- CN
- China
- Prior art keywords
- rpsa
- mice
- mouse
- sgrna
- swine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150008822 rpsA gene Proteins 0.000 title claims abstract description 31
- 238000010172 mouse model Methods 0.000 title claims abstract description 19
- 238000010276 construction Methods 0.000 title claims description 11
- 241000282898 Sus scrofa Species 0.000 claims abstract description 59
- 108091033409 CRISPR Proteins 0.000 claims abstract description 37
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000005516 engineering process Methods 0.000 claims abstract description 8
- 230000006801 homologous recombination Effects 0.000 claims abstract description 6
- 238000002744 homologous recombination Methods 0.000 claims abstract description 6
- 238000011740 C57BL/6 mouse Methods 0.000 claims abstract description 5
- 102100027271 40S ribosomal protein SA Human genes 0.000 claims abstract 6
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 claims abstract 6
- 241000699670 Mus sp. Species 0.000 claims description 64
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 33
- 230000008685 targeting Effects 0.000 claims description 24
- 108020004414 DNA Proteins 0.000 claims description 21
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 20
- 101100420078 Mus musculus Rpsa gene Proteins 0.000 claims description 15
- 235000013601 eggs Nutrition 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 10
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 8
- 238000010171 animal model Methods 0.000 claims description 8
- 241001529936 Murinae Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 101100420092 Sus scrofa RPSA gene Proteins 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 239000012502 diagnostic product Substances 0.000 claims description 2
- 238000009509 drug development Methods 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000012163 sequencing technique Methods 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000000047 product Substances 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 230000006798 recombination Effects 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 8
- 108020005004 Guide RNA Proteins 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- BOXNGMVEVOGXOJ-UBHSHLNASA-N Asp-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N BOXNGMVEVOGXOJ-UBHSHLNASA-N 0.000 description 4
- 208000001726 Classical Swine Fever Diseases 0.000 description 4
- VULNJDORNLBPNG-SWRJLBSHSA-N Thr-Glu-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O VULNJDORNLBPNG-SWRJLBSHSA-N 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000009437 off-target effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 2
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 2
- LZRNYBIJOSKKRJ-XVYDVKMFSA-N Ala-Asp-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LZRNYBIJOSKKRJ-XVYDVKMFSA-N 0.000 description 2
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 2
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 2
- WGDNWOMKBUXFHR-BQBZGAKWSA-N Ala-Gly-Arg Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N WGDNWOMKBUXFHR-BQBZGAKWSA-N 0.000 description 2
- LBYMZCVBOKYZNS-CIUDSAMLSA-N Ala-Leu-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O LBYMZCVBOKYZNS-CIUDSAMLSA-N 0.000 description 2
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 2
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 2
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 2
- GOWZVQXTHUCNSQ-NHCYSSNCSA-N Arg-Glu-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GOWZVQXTHUCNSQ-NHCYSSNCSA-N 0.000 description 2
- KRQSPVKUISQQFS-FJXKBIBVSA-N Arg-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N KRQSPVKUISQQFS-FJXKBIBVSA-N 0.000 description 2
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 2
- BXUHCIXDSWRSBS-CIUDSAMLSA-N Asn-Leu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BXUHCIXDSWRSBS-CIUDSAMLSA-N 0.000 description 2
- JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 2
- HRVQDZOWMLFAOD-BIIVOSGPSA-N Asp-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)O HRVQDZOWMLFAOD-BIIVOSGPSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- NQSUTVRXXBGVDQ-LKXGYXEUSA-N Cys-Asn-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NQSUTVRXXBGVDQ-LKXGYXEUSA-N 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 2
- LVNILKSSFHCSJZ-IHRRRGAJSA-N Gln-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LVNILKSSFHCSJZ-IHRRRGAJSA-N 0.000 description 2
- MFJAPSYJQJCQDN-BQBZGAKWSA-N Gln-Gly-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O MFJAPSYJQJCQDN-BQBZGAKWSA-N 0.000 description 2
- QMVCEWKHIUHTSD-GUBZILKMSA-N Gln-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N QMVCEWKHIUHTSD-GUBZILKMSA-N 0.000 description 2
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 2
- AKDOUBMVLRCHBD-SIUGBPQLSA-N Gln-Tyr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AKDOUBMVLRCHBD-SIUGBPQLSA-N 0.000 description 2
- VYOILACOFPPNQH-UMNHJUIQSA-N Gln-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N VYOILACOFPPNQH-UMNHJUIQSA-N 0.000 description 2
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 2
- YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 description 2
- HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 description 2
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 description 2
- ITVBKCZZLJUUHI-HTUGSXCWSA-N Glu-Phe-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ITVBKCZZLJUUHI-HTUGSXCWSA-N 0.000 description 2
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 2
- NTNUEBVGKMVANB-NHCYSSNCSA-N Glu-Val-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O NTNUEBVGKMVANB-NHCYSSNCSA-N 0.000 description 2
- FKJQNJCQTKUBCD-XPUUQOCRSA-N Gly-Ala-His Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O FKJQNJCQTKUBCD-XPUUQOCRSA-N 0.000 description 2
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 2
- XVYKMNXXJXQKME-XEGUGMAKSA-N Gly-Ile-Tyr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XVYKMNXXJXQKME-XEGUGMAKSA-N 0.000 description 2
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 2
- AVQNTYBAFBKMDL-WDSOQIARSA-N His-Pro-Trp Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O AVQNTYBAFBKMDL-WDSOQIARSA-N 0.000 description 2
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 2
- XENGULNPUDGALZ-ZPFDUUQYSA-N Ile-Asn-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N XENGULNPUDGALZ-ZPFDUUQYSA-N 0.000 description 2
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 2
- VISRCHQHQCLODA-NAKRPEOUSA-N Ile-Pro-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N VISRCHQHQCLODA-NAKRPEOUSA-N 0.000 description 2
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 2
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 2
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 2
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 2
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 2
- GPXFZVUVPCFTMG-AVGNSLFASA-N Leu-Arg-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(C)C GPXFZVUVPCFTMG-AVGNSLFASA-N 0.000 description 2
- CUXRXAIAVYLVFD-ULQDDVLXSA-N Leu-Arg-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUXRXAIAVYLVFD-ULQDDVLXSA-N 0.000 description 2
- GSSMYQHXZNERFX-WDSOQIARSA-N Leu-Met-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N GSSMYQHXZNERFX-WDSOQIARSA-N 0.000 description 2
- SWWCDAGDQHTKIE-RHYQMDGZSA-N Lys-Arg-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWWCDAGDQHTKIE-RHYQMDGZSA-N 0.000 description 2
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 2
- LNMKRJJLEFASGA-BZSNNMDCSA-N Lys-Phe-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LNMKRJJLEFASGA-BZSNNMDCSA-N 0.000 description 2
- MGKFCQFVPKOWOL-CIUDSAMLSA-N Lys-Ser-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N MGKFCQFVPKOWOL-CIUDSAMLSA-N 0.000 description 2
- AFFKUNVPPLQUGA-DCAQKATOSA-N Met-Leu-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O AFFKUNVPPLQUGA-DCAQKATOSA-N 0.000 description 2
- WPTHAGXMYDRPFD-SRVKXCTJSA-N Met-Lys-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O WPTHAGXMYDRPFD-SRVKXCTJSA-N 0.000 description 2
- LXCSZPUQKMTXNW-BQBZGAKWSA-N Met-Ser-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O LXCSZPUQKMTXNW-BQBZGAKWSA-N 0.000 description 2
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 2
- APKRGYLBSCWJJP-FXQIFTODSA-N Pro-Ala-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O APKRGYLBSCWJJP-FXQIFTODSA-N 0.000 description 2
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 2
- KPDRZQUWJKTMBP-DCAQKATOSA-N Pro-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 KPDRZQUWJKTMBP-DCAQKATOSA-N 0.000 description 2
- IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 2
- HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 2
- JZRYFUGREMECBH-XPUUQOCRSA-N Ser-Val-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O JZRYFUGREMECBH-XPUUQOCRSA-N 0.000 description 2
- JHBHMCMKSPXRHV-NUMRIWBASA-N Thr-Asn-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O JHBHMCMKSPXRHV-NUMRIWBASA-N 0.000 description 2
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 2
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 2
- AYCQVUUPIJHJTA-IXOXFDKPSA-N Thr-His-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O AYCQVUUPIJHJTA-IXOXFDKPSA-N 0.000 description 2
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 2
- OBAMASZCXDIXSS-SZMVWBNQSA-N Trp-Glu-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N OBAMASZCXDIXSS-SZMVWBNQSA-N 0.000 description 2
- SUEGAFMNTXXNLR-WFBYXXMGSA-N Trp-Ser-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O SUEGAFMNTXXNLR-WFBYXXMGSA-N 0.000 description 2
- YCQXZDHDSUHUSG-FJHTZYQYSA-N Trp-Thr-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 YCQXZDHDSUHUSG-FJHTZYQYSA-N 0.000 description 2
- WOAQYWUEUYMVGK-ULQDDVLXSA-N Tyr-Lys-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOAQYWUEUYMVGK-ULQDDVLXSA-N 0.000 description 2
- PHKQVWWHRYUCJL-HJOGWXRNSA-N Tyr-Phe-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PHKQVWWHRYUCJL-HJOGWXRNSA-N 0.000 description 2
- XLDYBRXERHITNH-QSFUFRPTSA-N Val-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)C(C)C XLDYBRXERHITNH-QSFUFRPTSA-N 0.000 description 2
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 2
- USLVEJAHTBLSIL-CYDGBPFRSA-N Val-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C USLVEJAHTBLSIL-CYDGBPFRSA-N 0.000 description 2
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 108010053037 kyotorphin Proteins 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010012058 leucyltyrosine Proteins 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- DIPIPFHFLPTCLK-LOKLDPHHSA-N Thr-Gln-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O DIPIPFHFLPTCLK-LOKLDPHHSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a preparation method of an RPSA gene modified swine-derived mouse, and particularly relates to a method for constructing a mouse model capable of expressing swine-derived RPSA by replacing a swine RPSA gene on a fertilized egg of a C57BL/6 background mouse by using homologous recombination and CRISPR/Cas9 technology.
Description
Technical Field
The invention belongs to the technical field of biological medicine, and particularly relates to a construction method of an RPSA gene pig-derived mouse model.
Background
Classical swine fever (Classical swine fever, CSF), also known as swine fever, is a viral disease with high infectivity and mortality caused by classical swine fever virus (Classical swine fever virus, CSFV), and has caused tremendous economic losses in the pig industry worldwide. The world animal health organization is used for determining the infectious diseases as A-type infectious diseases, and China is used for ranking the infectious diseases as A-type infectious diseases, so that the infectious diseases are one of main epidemic diseases which endanger the development of the pig industry in China at present.
Regarding host cell surface receptors that bind CSF viruses, laminin (RPSA) is one of the host cell attachment receptors for CSFV infection. RPSA (also known as LAMR 1) is a cell surface receptor with a highly conserved sequence that mediates high affinity interactions between laminin and cells. Notably, the overexpression of porcine RPSA in a variety of non-porcine kidney cell lines (BHK-21 and CHO-K1, etc.) was performed simultaneously, and no CSFV infection was observed, presumably RPSA only facilitates viral attachment to the cell surface and is an important, but not exclusive, binding receptor for CSFV infection.
In addition, in vitro experiments at home and abroad prove that RPSA inhibits replication of Foot-and-mouth disease virus (FMDV) by inhibiting MAPK signal transduction in FMDV infected cells in the process of Foot-and-mouth disease virus (Foot-and-mouth disease virus, FMDV) infection. Meanwhile, RPSA is a binding receptor for Dengue Virus (Dengue Virus) into hepatocytes.
At present, the effective means for preventing and treating classical swine fever is to kill the virus completely though China obtains better effect in controlling and eliminating classical swine fever by vaccination, and once epidemic situation is found, the virus is killed and treated harmlessly according to relevant regulation regulations of China, thus bringing huge economic pressure to pig industry in China. Under the background that CSFV infection epidemic situation is difficult to radically cure quickly, epidemic situation control mainly depends on strengthening biological safety guarantee precautionary measures of breeding enterprises, chinese swine fever epidemic situation prevention and control are normalized, toxic production is normalized, and how to closely monitor breeding environments also brings great challenges to pig industry.
Vaccine drug research and screening experiments need to be evaluated on animal models, rodents are the most widely applied experimental animal models, and because of small size, short growth and breeding period and easy operation, the vaccine drug research and screening experiments are one of the best experimental animal models, so that at present, no swine-derived mouse model prepared for swine-derived RPSA genes is available, the Rpsa genes of the mice are replaced by the RPSA genes of the pigs through a gene modification method, the Rpsa swine-derived mouse model is prepared, the vaccine drug research and screening method has the functional genes of the pigs, has very important significance for research on infection, invasion, immunity and the like of swine-derived related viruses, and can become an ideal animal model for screening and evaluating swine fever, foot-and-mouth disease and other related drugs and diagnostic products, and new ideas and strategies are brought to development of control epidemic situations.
The CRISPR/Cas9 system gene editing function is mainly applied to genome targeting of a plurality of species, and alleles are subjected to modification (such as knockout, mutation and knock-in) operation, so that various modification models can be quickly and efficiently built to study gene functions or build disease models. Although CRISPR/Cas9 gene editing systems have high cleavage efficiency, they have been commonly used in the creation of gene knockout models, but are faced with more complex genetic modification requirements, for example, when a longer fragment is targeted, the targeting efficiency is significantly reduced as the length of the knockin fragment increases, and if the sequence of the targeting region has a homologous structure in the mouse, a significant off-target effect occurs. In addition, when the CRISPR/Cas9 system containing the donor recombination fragment is directly subjected to micromanipulation on fertilized eggs, the donor fragment can be recombined at a target site, and also has a high probability of being randomly integrated into the genome of a mouse, the integrated site is random, high copy number knockin can occur, and the randomly integrated mouse can have unexpected phenotypes such as ectopic expression of an exogenous gene, silencing or activation of an endogenous gene at a non-target site and the like under the influence of the integrated site and the copy number, so that experimental results are interfered. Therefore, the recombination efficiency of CRISPR/Cas9 system is still to be further explored and optimized, and how to reduce or avoid the random integration probability of donor when targeting, and to increase the detection rate of random integration, certainly presents a series of challenges to gene editors.
Disclosure of Invention
A method of constructing a mouse model that can express porcine RPSA by replacing porcine RPSA with murine RPSA gene on fertilized eggs of C57BL/6 background mice using homologous recombination and CRISPR/Cas9 technology.
The specific technical scheme for realizing the invention is as follows:
a construction method of an RPSA gene pig-derived mouse model comprises the steps of replacing an RPSA gene of a pig with the RPSA of the mouse on a fertilized ovum of a C57BL/6 background mouse by homologous recombination and CRISPR/Cas9 technology, and constructing the mouse model capable of expressing the pig-derived RPSA.
The construction method of the RPSA gene swine-derived mouse model comprises the following steps:
1) According to the structure and function of the swine RPSA, the swine RPSA and mouse Rpsa coding regions are selected, the difference sites are identified, and the swine sequence for replacement is determined.
2) Determining a targeting site according to the mouse RPSA gene sequence determined in the step 1), and designing a homologous DNA donor containing the pig-source RPSA gene.
3) Preparing Cas9 or an expression vector thereof based on CRISPR/Cas9 technology; sgrnas for murine sequences were designed in the porcine replacement region. Designing and synthesizing to identify a 5 'end target site and a 3' end target site, and constructing an sgRNA expression vector.
4) And injecting the Cas9/sgRNA system and a targeting vector into fertilized eggs of mice, implanting the fertilized eggs into pseudopregnant female mice, and carrying out genetic identification after birth of the mice to obtain intermediate target mice (positive F0-generation mice).
Preferably, the amino acid sequence of the RPSA swine mice used for substitution is shown in SEQ No.2 (three different sites a241T, a272T and a290T, respectively).
Preferably, the mouse RPSA gene sequence determines the targeting sites to be exon6 and exon7 of the mouse RPSA gene.
Preferably, the 5 'and 3' sgRNA recognition sites are located within the mouse Rpsa gene intron3-4 and downstream of exon7, respectively.
Preferably, the construction of the sgRNA expression vector is performed by cloning the sgRNA sequence into the pUC57kan-T7-delG vector, and constructing the pUC57-sgRNA plasmid.
Preferably, the sgrnas are prepared by transcription by the following method: and (3) performing PCR (polymerase Star or PrimerStar Max) by taking a sgRNA-F, sgRNA-R as a primer and taking a puc57-sgRNA plasmid with correct sequencing as a template, purifying a PCR product, and preparing the sgRNA transcription preparation template. Transcription of sgrnas was performed using the T7-ShortScript in vitro transcription kit (AM 1354).
Preferably, 0.5 day mice fertilized egg targeting vector injection is used.
Preferably, the obtained positive F0 generation mice are bred with wild type C57BL/6J mice, and the born mice are subjected to genotype identification to obtain the RPSA swine-derived mice animal model capable of being inherited stably.
Preferably, the positive swine-derived mice obtained are genotyping identified. And (5) identifying by PCR and sequencing and identifying the PCR product.
A construction method of an RPSA gene pig-derived mouse model comprises the following steps:
1) Exon6 and exon7 of the mouse Rpsa gene were selected as targeting sites and a homologous DNA donor containing the porcine Rpsa gene was designed.
2) Preparing Cas9 or an expression vector thereof; sgrnas for murine sequences were designed in the porcine replacement region. Designing and synthesizing to identify a 5 'end target site and a 3' end target site, and constructing an sgRNA expression vector. The sgRNA recognition sites at both ends are located within the mouse Rpsa gene intron3-4, and downstream of exon7, respectively.
3) The Cas9/sgRNA system and the targeting vector are injected into fertilized eggs of mice for 0.5 day, transplanted into pseudopregnant female mice, and after the mice are born, the gene identification is carried out to obtain the intermediate target positive mice (positive F0 generation mice).
Furthermore, the obtained positive F0 generation mice and wild type C57BL/6J mice can be matched and propagated, and the born mice are subjected to genotype identification to obtain the RPSA swine-derived mice animal model which can be inherited stably.
Further, the target site sequence of the gRNA on the RPSA in step 2) is shown in the following table:
TABLE 1 sgRNA sequences
sgRNA name | sgRNA sequence (5 '. Fwdarw.3') | PAM |
Rpsa-5S1 | GAGATAGTTTTGGTACGTGG | TGG |
Rpsa-5S2 | GTTGAGATAGTTTTGGTACG | TGG |
Rpsa-3S1 | ATTACGGCCACAGCCTATTA | AGG |
Rpsa-3S2 | ATCTACTCATATTCCTTAAT | AGG |
Each sgRNA sequence was cloned into pUC57kan-T7-delG vector to construct a pUC57-sgRNA plasmid.
Furthermore, the sgRNA transcription preparation method is to use PrimerStar or PrimerStar Max system, sgRNA-F, sgRNA-R as a primer, and the properly sequenced puc57-sgRNA plasmid as a template to carry out PCR, and purify the PCR product to prepare the sgRNA transcription preparation template. Transcription of sgrnas was performed using the T7-ShortScript in vitro transcription kit (AM 1354).
Further, the pig-derived mice are identified for genotype.
Further, genotyping of swine mice includes: the obtained rat tail genomic DNA of the positive mice was designed and PCR identification after mid-targeting was performed using two pairs of primers, respectively. The genotyping primers designed and used are shown in the following table.
Table 2 RPSA pig-derived mouse genotype identification primers
Note that: KI is the mid-target genotype; WT is wild-type.
The primer Rpsa-wt-tF1/Rpsa-wt-tR1 was located outside the 5' homology arm and inside the intron6-7, respectively, and the PCR product resulting from the amplification of this primer was sequenced. Sequencing and analyzing the targeting region and the exon6 swine derived site, and if the targeting region is consistent with the theoretical sequence, indicating that the target vector is effectively recombined at the 5' of the mouse genome; the PCR products from this primer amplification were sequenced with Rpsa-wt-tF2/Rpsa-wt-tR2 located outside the intron6-7 and 3' homology arms, respectively, and the sequencing primers are described in Table 3 below. Sequencing analysis of the targeting region and the exon7 swine derived site, consistent with the theoretical sequence, shows that the target vector is effectively recombined in the 3' of the mouse genome. Mice positive for both-end PCR amplification and sequencing were positive mice.
TABLE 3 sequencing primers
Primer name | Primer sequences | |
Rpsa-wt-tF3 | CTGCCATTTGGGTGTGTGGAAT(SEQID NO.13) | Sequencing of 5' full Length product |
Rpsa-wt-seqR1 | AACCCATGTGTTCACATGCTTA(SEQID NO.14) | Sequencing of 3' full Length product |
Further, QPCR was performed on mice positive for the target.
Drawings
Fig. 1: and constructing a targeting strategy of a mouse model capable of expressing the pig-derived RPSA.
Fig. 2: identifying an electrophoresis pattern of pRPSA PCR 5 end and pRPSA 3 end, wherein a WT negative control is genomic DNA; TRANS 2K PLUS II band: 5000bp, 3000bp, 2000bp, 1000bp, 750bp, 500bp, 250bp, 100bp.
Fig. 3: pRPSA PCR 5-end sequencing alignment map.
Fig. 4: pRPSA PCR 3 end 272 th codon locus sequencing alignment map.
Fig. 5: pRPSA PCR 3 end 290 th codon site sequencing alignment map.
The CRISPR/Cas9 gene editing system has high cutting activity, is designed and constructed aiming at a target gene, can guide Cas9 protein to carry out high-efficiency cutting at a target gene locus, so as to manufacture a gene knockout model, and if exogenous sequences need to be knocked in the target gene locus, a recombination donor vector needs to be constructed simultaneously, the vector needs to comprise homologous arm structures and insertion fragments at two sides of an insertion locus, and the vector is injected into fertilized eggs together with the sgRNA and the Cas9 for recombination through the in vitro constructed donor vector.
The Rpsa gene of the mouse is positioned on chromosome 9, a structure homologous to Rpsa of the mouse exists in a plurality of chromosome sites such as chromosome 3, chromosome 17, chromosome 10, chromosome X, chromosome 4 and chromosome 14, a gRNA is designed in a region where point mutation is located, a target-off effect is inevitably brought, in order to avoid the target-off caused by homologous sequences, the target-off region is expanded, gRNA sites are designed at the downstream of intron3-4 and exon7 of the Rpsa gene respectively, so that the specificity of sequences of homologous arms and cleavage sites is ensured, but the longer the insert, the lower the recombination efficiency is, and in general cases, the recombination difficulty is greatly improved when the length of the insert is greater than 1 kb. And the gRNA is designed at the site of exogenous gene insertion, the donor is manufactured, the closer the gRNA is to the knock-in site, the higher the recombination efficiency is, the length of the donor gene sequence designed for avoiding the off-target effect is 3424bp, and the mice offspring obtained after microinjection and transplantation are successfully verified to obtain the positive mice (F0 generation) through detection means of PCR and sequencing.
The invention verifies the correct integration of target site genes by PCR and sequencing methods, and simultaneously carries out QPCR detection on mice with positive target, detects the possibility of other site integration in the genome of the mice, and further verifies that positive mice are correct targets, and other non-target sites of the positive mice are inserted randomly.
The mouse provided by the invention has the pig functional genes, the knocked-in genes are from pig RPSA genes and are knocked in the Rpsa gene locus of the mouse, and as the self regulatory elements of the mouse are reserved, the self regulatory mechanism of the mouse is utilized to control the expression of pig RPSA, meanwhile, the Rpsa genes of the mouse are silenced, and the cross reaction of medicines caused by the species amino acid homology relationship can be avoided. The model has the functional genes of pigs, and has important guiding significance for researches such as infection, invasion, immunity, drug development and the like of swine related viruses.
The construction method for constructing the mouse model capable of expressing the swine RPSA by replacing the swine RPSA gene on the fertilized eggs of the C57BL/6 background mice by using the homologous recombination and CRISPR/Cas9 technology has the advantages of high recombination efficiency, reduction or avoidance of the random integration probability of the donor during targeting, high detection rate of random integration and capability of accurately and efficiently constructing the RPSA gene swine mouse model.
Detailed Description
The following examples illustrate the specific steps of the present invention, but are not limited thereto.
The terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art unless otherwise indicated.
The invention is described in further detail below in connection with specific embodiments and with reference to the data. It should be understood that the following examples are intended to illustrate the invention and are not intended to limit the scope of the invention in any way.
In the following examples, various processes and methods, which are not described in detail, are conventional methods well known in the art.
The invention will be further illustrated with reference to specific examples.
Example 1 determination of the substitution region of the obtained porcine fragment and the inserted porcine sequence
According to the structure and function of the swine RPSA, three differential sites of swine RPSA and mouse Rpsa coding regions are selected, the three differential sites of the swine RPSA gene are respectively A241T, A272T and A290T, the other regions all retain the murine structure, and the wild type sequence of the mouse is shown as SEQ No. 1. SEQ No.1:
Msgaldvlqmkeedvlkflaagthlggtnldfqmeqyiykrksdgiyiinlkrtweklllaaraivaienpadvsvissrntgqravlkfaaatgatpiagrftpgtftnqiqaafreprllvvtdpradhqplteasyvnlptialcntdsplryvdiaipcnnkgahsvglmwwmlarevlrmrgtisrehpwevmpdlyfyrdpeeiekeeqaaaekavtkeefqgewtapapeftaaqpevadwsegvqvpsvpiqqfptedwsaqpatedwsaaptaqatewvgattews
the corresponding nucleotide sequence is SEQ ID NO.3:
ATGTCCGGAGCCCTTGACGTCCTGCAGATGAAGGAGGAGGATGTCCTCAAATTCCTTGCTGCGGGAACCCACTTAGGTGGCACCAACCTTGACTTTCAGATGGAGCAGTACATCTACAAAAGGAAAAGTGACGGTATCTACATCATAAACCTGAAGAGGACCTGGGAGAAGCTGTTGCTCGCAGCTCGAGCTATTGTTGCCATCGAGAATCCTGCTGACGTCAGCGTCATCTCCTCCAGGAACACTGGCCAGCGAGCTGTGCTGAAGTTTGCTGCTGCCACAGGAGCCACTCCGATCGCTGGCCGCTTCACACCTGGGACCTTCACTAACCAGATCCAAGCAGCCTTCAGGGAGCCACGGCTTCTAGTGGTGACCGATCCCAGGGCTGACCATCAGCCACTCACAGAGGCCTCTTATGTCAACCTGCCCACCATTGCTCTGTGTAACACAGATTCTCCCCTGCGCTATGTGGACATTGCCATCCCATGCAACAACAAGGGAGCTCACTCAGTGGGTCTGATGTGGTGGATGCTGGCCAGGGAAGTACTCCGCATGCGAGGTACTATCTCCCGTGAGCACCCCTGGGAGGTCATGCCTGATCTTTACTTCTACAGAGACCCAGAGGAGATTGAGAAGGAGGAGCAGGCTGCTGCTGAGAAGGCTGTGACCAAGGAGGAATTCCAGGGTGAATGGACCGCACCAGCTCCTGAGTTCACTGCTGCTCAGCCTGAGGTGGCCGACTGGTCTGAGGGTGTGCAGGTTCCCTCTGTGCCCATCCAGCAGTTCCCCACGGAAGACTGGAGTGCACAGCCAGCCACTGAGGATTGGTCAGCAGCTCCCACAGCGCAGGCCACTGAGTGGGTTGGAGCCACCACTGAGTGGTCCTGA
EXAMPLE 2 determination of the porcine-derived RPSA protein sequence obtained
And (3) replacing the corresponding region of the B6 murine Rpsa with three different sites of the porcine RPSA gene by utilizing homologous recombination, wherein the rest sequences all keep the sequence of the B6 mouse, and the amino acid sequence of the RPSA porcine mice with successful targeting is shown as SEQ No. 2.
SEQ No.2:
###
ATGTCCGGAGCCCTTGACGTCCTGCAGATGAAGGAGGAGGATGTCCTCAAATTCCTTGCTGCGGGAACCCACTTAGGTGGCACCAACCTTGACTTTCAGATGGAGCAGTACATCTACAAAAGGAAAAGTGACGGTATCTACATCATAAACCTGAAGAGGACCTGGGAGAAGCTGTTGCTCGCAGCTCGAGCTATTGTTGCCATCGAGAATCCTGCTGACGTCAGCGTCATCTCCTCCAGGAACACTGGCCAGCGAGCTGTGCTGAAGTTTGCTGCTGCCACAGGAGCCACTCCGATCGCTGGCCGCTTCACACCTGGGACCTTCACTAACCAGATCCAAGCAGCCTTCAGGGAGCCACGGCTTCTAGTGGTGACCGATCCCAGGGCTGACCATCAGCCACTCACAGAGGCCTCTTATGTCAACCTGCCCACCATTGCTCTGTGTAACACAGATTCTCCCCTGCGCTATGTGGACATTGCCATCCCATGCAACAACAAGGGAGCTCACTCAGTGGGTCTGATGTGGTGGATGCTGGCCAGGGAAGTACTCCGCATGCGAGGTACTATCTCCCGTGAGCACCCCTGGGAGGTCATGCCTGATCTTTACTTCTACAGAGACCCAGAGGAGATTGAGAAGGAGGAGCAGGCTGCTGCTGAGAAGGCTGTGACCAAGGAGGAATTCCAGGGTGAATGGACCGCACCAGCTCCTGAGTTCACTGCTACTCAGCCTGAGGTGGCCGACTGGTCTGAGGGTGTGCAGGTTCCCTCTGTGCCCATCCAGCAGTTCCCCACGGAAGACTGGAGTGCACAGCCAACCACTGAGGATTGGTCAGCAGCTCCCACAGCGCAGGCCACTGAGTGGGTTGGAACAACCACTGAGTGGTCCTGA
EXAMPLE 3 vector injection grafting Positive mice were obtained
1) Selecting exon6 and exon7 of the Rpsa gene of the mouse as target sites, and designing a homologous DNA donor containing the RPSA gene of a pig source and an identification scheme;
2) Preparing Cas9 or an expression vector thereof based on CRISPR/Cas9 technology; sgrnas for murine sequences were designed in the porcine replacement region. Designing and synthesizing to identify a 5 'end target site and a 3' end target site, and constructing an sgRNA expression vector. The recognition sites for the sgrnas at both ends are located within the mouse Rpsa gene intron3-4, and downstream from exon7, respectively, and the target site sequences for each sgRNA on Rpsa are shown in table 1. Each sgRNA sequence was cloned into pUC57kan-T7-delG vector to construct a pUC57-sgRNA plasmid.
TABLE 1 sgRNA sequences
sgRNA name | sgRNA sequence (5 '. Fwdarw.3') | PAM |
Rpsa-5S1 | GAGATAGTTTTGGTACGTGG | TGG |
Rpsa-5S2 | GTTGAGATAGTTTTGGTACG | TGG |
Rpsa-3S1 | ATTACGGCCACAGCCTATTA | AGG |
Rpsa-3S2 | ATCTACTCATATTCCTTAAT | AGG |
The preparation method of sgRNA transcription comprises the following steps: and (3) performing PCR (polymerase Star or PrimerStar Max) by taking a sgRNA-F, sgRNA-R as a primer and taking a puc57-sgRNA plasmid with correct sequencing as a template, purifying a PCR product, and preparing the sgRNA transcription preparation template. Transcription of sgrnas was performed using the T7-ShortScript in vitro transcription kit (AM 1354).
3) The Cas9/sgRNA system and the targeting vector are injected into fertilized eggs of mice for 0.5 day, transplanted into pseudopregnant female mice, and after the mice are born, the medium-target mice screened by the gene identification are positive F0-generation mice.
4) And breeding the obtained positive F0-generation mice and wild C57BL/6J mice, and carrying out genotype identification on the born mice to obtain the RPSA swine-derived mice animal model capable of being inherited stably.
Example 4 porcine-derived mice were genotyping.
Performing PCR identification (the details of the primers are shown in table 2) after the obtained rat tail genome DNA of the positive rat is subjected to mid-targeting by using two pairs of primers, wherein the primers Rpsa-wt-tF1/Rpsa-wt-tR1 are respectively positioned outside a 5 'homology arm and in intron6-7, sequencing a PCR product generated by amplifying the primers (the details of the sequencing primers are shown in table 3), sequencing and analyzing a targeting region and an exon6 swine-derived site, and indicating that the target vector is effectively recombined in the 5' of the rat genome when the target vector is consistent with a theoretical sequence; rpsa-wt-tF2/Rpsa-wt-tR2 are respectively positioned outside the intron6-7 and 3 'homology arms, and the PCR products generated by the primer amplification are sequenced (the sequencing primer is shown in Table 3), the sequencing analysis targeting region and the exon7 swine derived site are consistent with the theoretical sequence, so that the target vector is effectively recombined in the 3' of the mouse genome. Mice positive for both-end PCR amplification and sequencing were positive mice.
Table 2 RPSA pig-derived mouse genotype identification primers
Note that: KI is the mid-target genotype; WT is wild-type.
TABLE 3 sequencing primers
Primer name | Primer sequences | |
Rpsa-wt-tF3 | CTGCCATTTGGGTGTGTGGAAT | Sequencing of 5' full Length product |
Rpsa-wt-seqR1 | AACCCATGTGTTCACATGCTTA | Sequencing of 3' full Length product |
The PCR reaction system and the reaction conditions are shown in the following table:
TABLE 4 PCR reaction System
Reagent (Vazyme P112-03) | Volume (mul) | Specification of specification |
2×Taq Master Mix,Dye Plus | 12.5 | \ |
ddH2O | 9.5 | \ |
Primer A(10pmol/μl) | 1 | 10pmol/μl |
Primer B(10pmol/μl) | 1 | 10pmol/μl |
Template(≈100ng/μl) | 1 | ≈100ng/μl |
TABLE 5 PCR reaction conditions
EXAMPLE 5QPCR
pRPSA mouse model PCR identification results:
the PCR amplification results of the 5-end and the 3-end are shown in the figure 2, and the figure 2 shows the identification electrophoresis patterns of the 5-end and the 3-end of pRPSA PCR. WT negative control is genomic DNA; TRANS 2K PLUS II band: 5000bp, 3000bp, 2000bp, 1000bp, 750bp, 500bp, 250bp, 100bp.
The pRPSA PCR 5-end sequencing comparison map is shown in the figure 3, the arrow indicates the mutation site of the exon6 swine origin site, and the 241 th codon is mutated from GCT to ACT;
the sequencing comparison map of the 272 rd codon of the pRPSA PCR 3 end is shown in figures 4 and 5, the shading indicates the mutation site of the exon7 swine origin site, the 272 rd codon is mutated from GCC to ACC, and the 290 th codon is mutated from GCC to ACA;
results: successful acquisition of B6 background 3 positive mice were obtained. pRPSA rat DNA identification electrophoretogram, 5 'and 3' identification of target bands were positive, and sequencing comparison showed positive mice with correct mid-target.
The Cas9/sgRNA system and targeting vector were injected into fertilized eggs of 0.5 day mice, a total of 3 microinjection and transplantation were performed, and the three transplantation had 9, 9 and 17F 0 mice, respectively, and since the existing data (MGI) showed that homozygous mice knocked out the Rpsa gene had a phenotype of embryonic death, the birth rate was significantly lower from the data shown by the three transplantation. After further PCR and sequencing detection, 1, 0 and 2 positive mice are obtained respectively, and the overall positive rate is 8.6%.
The transplantation, birth and positive rates are shown in Table 6 below.
TABLE 6 transplantation, birth and Positive Rate
From the above results, it can be seen that the gRNA designed near the point mutation effectively avoids the off-target effect, and the gRNA with the expanded targeting region is involved, so that the specificity of the homology arm and the cleavage site sequence can be ensured, and the recombination efficiency is high. Meanwhile, through verification, the condition that positive mice have orthotopic forward recombination is eliminated, and the positive mice are ensured to be correctly targeted without random insertion of other non-target sites.
Sequence listing
<110> Jiangsu Jizhikang biotechnology Co., ltd
<120> construction method of RPSA gene pig-derived mouse model
<130> 20210125
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 295
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 1
Met Ser Gly Ala Leu Asp Val Leu Gln Met Lys Glu Glu Asp Val Leu
1 5 10 15
Lys Phe Leu Ala Ala Gly Thr His Leu Gly Gly Thr Asn Leu Asp Phe
20 25 30
Gln Met Glu Gln Tyr Ile Tyr Lys Arg Lys Ser Asp Gly Ile Tyr Ile
35 40 45
Ile Asn Leu Lys Arg Thr Trp Glu Lys Leu Leu Leu Ala Ala Arg Ala
50 55 60
Ile Val Ala Ile Glu Asn Pro Ala Asp Val Ser Val Ile Ser Ser Arg
65 70 75 80
Asn Thr Gly Gln Arg Ala Val Leu Lys Phe Ala Ala Ala Thr Gly Ala
85 90 95
Thr Pro Ile Ala Gly Arg Phe Thr Pro Gly Thr Phe Thr Asn Gln Ile
100 105 110
Gln Ala Ala Phe Arg Glu Pro Arg Leu Leu Val Val Thr Asp Pro Arg
115 120 125
Ala Asp His Gln Pro Leu Thr Glu Ala Ser Tyr Val Asn Leu Pro Thr
130 135 140
Ile Ala Leu Cys Asn Thr Asp Ser Pro Leu Arg Tyr Val Asp Ile Ala
145 150 155 160
Ile Pro Cys Asn Asn Lys Gly Ala His Ser Val Gly Leu Met Trp Trp
165 170 175
Met Leu Ala Arg Glu Val Leu Arg Met Arg Gly Thr Ile Ser Arg Glu
180 185 190
His Pro Trp Glu Val Met Pro Asp Leu Tyr Phe Tyr Arg Asp Pro Glu
195 200 205
Glu Ile Glu Lys Glu Glu Gln Ala Ala Ala Glu Lys Ala Val Thr Lys
210 215 220
Glu Glu Phe Gln Gly Glu Trp Thr Ala Pro Ala Pro Glu Phe Thr Ala
225 230 235 240
Ala Gln Pro Glu Val Ala Asp Trp Ser Glu Gly Val Gln Val Pro Ser
245 250 255
Val Pro Ile Gln Gln Phe Pro Thr Glu Asp Trp Ser Ala Gln Pro Ala
260 265 270
Thr Glu Asp Trp Ser Ala Ala Pro Thr Ala Gln Ala Thr Glu Trp Val
275 280 285
Gly Ala Thr Thr Glu Trp Ser
290 295
<210> 2
<211> 295
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 2
Met Ser Gly Ala Leu Asp Val Leu Gln Met Lys Glu Glu Asp Val Leu
1 5 10 15
Lys Phe Leu Ala Ala Gly Thr His Leu Gly Gly Thr Asn Leu Asp Phe
20 25 30
Gln Met Glu Gln Tyr Ile Tyr Lys Arg Lys Ser Asp Gly Ile Tyr Ile
35 40 45
Ile Asn Leu Lys Arg Thr Trp Glu Lys Leu Leu Leu Ala Ala Arg Ala
50 55 60
Ile Val Ala Ile Glu Asn Pro Ala Asp Val Ser Val Ile Ser Ser Arg
65 70 75 80
Asn Thr Gly Gln Arg Ala Val Leu Lys Phe Ala Ala Ala Thr Gly Ala
85 90 95
Thr Pro Ile Ala Gly Arg Phe Thr Pro Gly Thr Phe Thr Asn Gln Ile
100 105 110
Gln Ala Ala Phe Arg Glu Pro Arg Leu Leu Val Val Thr Asp Pro Arg
115 120 125
Ala Asp His Gln Pro Leu Thr Glu Ala Ser Tyr Val Asn Leu Pro Thr
130 135 140
Ile Ala Leu Cys Asn Thr Asp Ser Pro Leu Arg Tyr Val Asp Ile Ala
145 150 155 160
Ile Pro Cys Asn Asn Lys Gly Ala His Ser Val Gly Leu Met Trp Trp
165 170 175
Met Leu Ala Arg Glu Val Leu Arg Met Arg Gly Thr Ile Ser Arg Glu
180 185 190
His Pro Trp Glu Val Met Pro Asp Leu Tyr Phe Tyr Arg Asp Pro Glu
195 200 205
Glu Ile Glu Lys Glu Glu Gln Ala Ala Ala Glu Lys Ala Val Thr Lys
210 215 220
Glu Glu Phe Gln Gly Glu Trp Thr Ala Pro Ala Pro Glu Phe Thr Ala
225 230 235 240
Thr Gln Pro Glu Val Ala Asp Trp Ser Glu Gly Val Gln Val Pro Ser
245 250 255
Val Pro Ile Gln Gln Phe Pro Thr Glu Asp Trp Ser Ala Gln Pro Thr
260 265 270
Thr Glu Asp Trp Ser Ala Ala Pro Thr Ala Gln Ala Thr Glu Trp Val
275 280 285
Gly Thr Thr Thr Glu Trp Ser
290 295
<210> 3
<211> 888
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 3
atgtccggag cccttgacgt cctgcagatg aaggaggagg atgtcctcaa attccttgct 60
gcgggaaccc acttaggtgg caccaacctt gactttcaga tggagcagta catctacaaa 120
aggaaaagtg acggtatcta catcataaac ctgaagagga cctgggagaa gctgttgctc 180
gcagctcgag ctattgttgc catcgagaat cctgctgacg tcagcgtcat ctcctccagg 240
aacactggcc agcgagctgt gctgaagttt gctgctgcca caggagccac tccgatcgct 300
ggccgcttca cacctgggac cttcactaac cagatccaag cagccttcag ggagccacgg 360
cttctagtgg tgaccgatcc cagggctgac catcagccac tcacagaggc ctcttatgtc 420
aacctgccca ccattgctct gtgtaacaca gattctcccc tgcgctatgt ggacattgcc 480
atcccatgca acaacaaggg agctcactca gtgggtctga tgtggtggat gctggccagg 540
gaagtactcc gcatgcgagg tactatctcc cgtgagcacc cctgggaggt catgcctgat 600
ctttacttct acagagaccc agaggagatt gagaaggagg agcaggctgc tgctgagaag 660
gctgtgacca aggaggaatt ccagggtgaa tggaccgcac cagctcctga gttcactgct 720
gctcagcctg aggtggccga ctggtctgag ggtgtgcagg ttccctctgt gcccatccag 780
cagttcccca cggaagactg gagtgcacag ccagccactg aggattggtc agcagctccc 840
acagcgcagg ccactgagtg ggttggagcc accactgagt ggtcctga 888
<210> 4
<211> 888
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 4
atgtccggag cccttgacgt cctgcagatg aaggaggagg atgtcctcaa attccttgct 60
gcgggaaccc acttaggtgg caccaacctt gactttcaga tggagcagta catctacaaa 120
aggaaaagtg acggtatcta catcataaac ctgaagagga cctgggagaa gctgttgctc 180
gcagctcgag ctattgttgc catcgagaat cctgctgacg tcagcgtcat ctcctccagg 240
aacactggcc agcgagctgt gctgaagttt gctgctgcca caggagccac tccgatcgct 300
ggccgcttca cacctgggac cttcactaac cagatccaag cagccttcag ggagccacgg 360
cttctagtgg tgaccgatcc cagggctgac catcagccac tcacagaggc ctcttatgtc 420
aacctgccca ccattgctct gtgtaacaca gattctcccc tgcgctatgt ggacattgcc 480
atcccatgca acaacaaggg agctcactca gtgggtctga tgtggtggat gctggccagg 540
gaagtactcc gcatgcgagg tactatctcc cgtgagcacc cctgggaggt catgcctgat 600
ctttacttct acagagaccc agaggagatt gagaaggagg agcaggctgc tgctgagaag 660
gctgtgacca aggaggaatt ccagggtgaa tggaccgcac cagctcctga gttcactgct 720
actcagcctg aggtggccga ctggtctgag ggtgtgcagg ttccctctgt gcccatccag 780
cagttcccca cggaagactg gagtgcacag ccaaccactg aggattggtc agcagctccc 840
acagcgcagg ccactgagtg ggttggaaca accactgagt ggtcctga 888
<210> 5
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 5
gagatagttt tggtacgtgg 20
<210> 6
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 6
gttgagatag ttttggtacg 20
<210> 7
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 7
attacggcca cagcctatta 20
<210> 8
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 8
atctactcat attccttaat 20
<210> 9
<211> 23
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 9
aaagtgacgg tcagttgcca cct 23
<210> 10
<211> 22
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 10
actgtaaaag ctccctggca gc 22
<210> 11
<211> 26
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 11
ggatacactg tgtcttgaca ctgctc 26
<210> 12
<211> 23
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 12
cacttggaga ctctgggaaa gct 23
<210> 13
<211> 22
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 13
ctgccatttg ggtgtgtgga at 22
<210> 14
<211> 22
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 14
aacccatgtg ttcacatgct ta 22
Claims (3)
1. A construction method of an RPSA gene pig-derived mouse model is characterized in that the pig RPSA is replaced with the mouse RPSA gene on fertilized eggs of a C57BL/6 background mouse by homologous recombination and CRISPR/Cas9 technology, and a mouse model capable of expressing pig-derived RPSA is constructed;
the method comprises the following steps:
1) According to the structure and the function of the swine RPSA, selecting swine RPSA and mouse Rpsa coding regions, identifying difference sites and determining swine sequences for replacement;
the amino acid sequence of the RPSA swine-derived mice used for replacement is shown as SEQ ID No. 2;
2) Determining a targeting site according to the mouse RPSA gene sequence determined in the step 1), and designing a homologous DNA donor containing the pig-source RPSA gene;
the mouse RPSA gene sequence determines that the targeting sites are exon6 and exon7 of the mouse Rpsa gene;
3) Preparing Cas9 or an expression vector thereof based on CRISPR/Cas9 technology; designing sgRNA aiming at a murine sequence in a swine-derived substitution region, designing and synthesizing and identifying a 5 '-end target site and a 3' -end target site, and constructing a sgRNA expression vector;
the sgRNA sequence is as follows:
Rpsa-5S1:GAGATAGTTTTGGTACGTGG
Rpsa-5S2:GTTGAGATAGTTTTGGTACG
Rpsa-3S1:ATTACGGCCACAGCCTATTA
Rpsa-3S2:ATCTACTCATATTCCTTAAT;
the 5 'and 3' sgRNA recognition sites are located within the mouse Rpsa gene intron3-4 and downstream of exon7, respectively;
constructing a sgRNA expression vector, namely cloning a sgRNA sequence into a pUC57kan-T7-delG vector, and constructing a pUC57-sgRNA plasmid;
4) Injecting the Cas9/sgRNA system and the targeting vector into fertilized eggs of mice for 0.5 day, implanting the fertilized eggs into pseudopregnant female mice, carrying out genetic identification after the mice are born, obtaining a medium-target mice, namely positive F0-generation mice, carrying out mating propagation on the obtained positive F0-generation mice and wild type C57BL/6J mice, and carrying out genotype identification on the born mice to obtain the RPSA swine-derived mice animal model capable of being inherited stably.
2. Use of the construction method of claim 1 for obtaining a mouse model for vaccine drug development, said use being for non-disease diagnosis or treatment purposes.
3. Use according to claim 2 for screening or evaluating drugs and diagnostic products related to swine fever or foot and mouth disease for non-disease diagnostic or therapeutic purposes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021101151140 | 2021-01-28 | ||
CN202110115114 | 2021-01-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114574526A CN114574526A (en) | 2022-06-03 |
CN114574526B true CN114574526B (en) | 2024-03-12 |
Family
ID=81769642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210005243.9A Active CN114574526B (en) | 2021-01-28 | 2022-01-04 | Construction method of RPSA gene pig-derived mouse model |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114574526B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116716349B (en) * | 2023-08-01 | 2023-10-31 | 江苏集萃药康生物科技股份有限公司 | Construction method and application of DLL4 humanized mouse model |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727880A (en) * | 2004-06-01 | 2012-10-17 | 西奈山医学院 | Genetically engineered swine influenza virus and uses thereof |
CN107502612A (en) * | 2017-09-30 | 2017-12-22 | 厦门大学 | It is a kind of to identify with reference to WSSV laminin receptor gene C q LR and preparation method and application |
CN108949763A (en) * | 2018-08-15 | 2018-12-07 | 吉林大学 | Accurate mutation LamR gene and the application of swine fever virus infection can effectively be inhibited |
CN109266656A (en) * | 2018-10-10 | 2019-01-25 | 江苏集萃药康生物科技有限公司 | A kind of construction method of PD1 humanization BALB/c mouse model and its application |
CN109929875A (en) * | 2019-03-12 | 2019-06-25 | 江苏集萃药康生物科技有限公司 | A kind of construction method of LAG3 gene humanized animal's model and its application |
CN110106205A (en) * | 2019-05-10 | 2019-08-09 | 江苏集萃药康生物科技有限公司 | A kind of construction method of GITR humanized animal model and its application |
CA3092459A1 (en) * | 2018-03-02 | 2019-09-06 | Generation Bio Co. | Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes |
-
2022
- 2022-01-04 CN CN202210005243.9A patent/CN114574526B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727880A (en) * | 2004-06-01 | 2012-10-17 | 西奈山医学院 | Genetically engineered swine influenza virus and uses thereof |
CN107502612A (en) * | 2017-09-30 | 2017-12-22 | 厦门大学 | It is a kind of to identify with reference to WSSV laminin receptor gene C q LR and preparation method and application |
CA3092459A1 (en) * | 2018-03-02 | 2019-09-06 | Generation Bio Co. | Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes |
CN108949763A (en) * | 2018-08-15 | 2018-12-07 | 吉林大学 | Accurate mutation LamR gene and the application of swine fever virus infection can effectively be inhibited |
CN109266656A (en) * | 2018-10-10 | 2019-01-25 | 江苏集萃药康生物科技有限公司 | A kind of construction method of PD1 humanization BALB/c mouse model and its application |
CN109929875A (en) * | 2019-03-12 | 2019-06-25 | 江苏集萃药康生物科技有限公司 | A kind of construction method of LAG3 gene humanized animal's model and its application |
CN110106205A (en) * | 2019-05-10 | 2019-08-09 | 江苏集萃药康生物科技有限公司 | A kind of construction method of GITR humanized animal model and its application |
Non-Patent Citations (8)
Title |
---|
CRISPR/Cas9介导的RPSA基因敲除细胞系的建立及其应用;高利利;微生物学报;1945-1956 * |
Genetically modified pigs are protected from classical swine fever virus;Zicong Xie;plos pathogens;20181213;全文 * |
Mus musculus ribosomal protein SA (Rpsa), mRNA,Accession NO.NM_011029.4;Kumazoe M;Genbank Database;1-4 * |
Recombinant Swinepox Virus Expressing Glycoprotein E2 of Classical Swine Fever Virus Confers Complete Protection in Pigs upon Viral Challenge;Huixing Lin;Veterinary Infectious Diseases;20170530;全文 * |
RPSA distribution and expression in tissues and immune cells of pathogen-infected mice;Liu M;Microb Pathog;104609 * |
Sus scrofa ribosomal protein SA (RPSA), Mrna, Accession NO. NM_001037146.2;Chen J;Genbank Database;1-4 * |
Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing;Wang X;Gene;20201026;全文 * |
基于CRISPR/Cas9的抗猪瘟病毒猪的制备;谢子聪;中国博士学位论文全文数据库(电子期刊)农业科技辑;摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN114574526A (en) | 2022-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105861554B (en) | method for realizing animal sex control based on editing Rbmy gene and application | |
CN106282231B (en) | Construction method and application of mucopolysaccharide storage disease type II animal model | |
CN109197781B (en) | Construction method of AURKA-CKO1-N conditional gene knockout mouse model | |
CN110257435B (en) | Construction method and application of PROM1-KO mouse model | |
CN111019971A (en) | Construction method of mouse model for conditionally overexpressing HPV E6 gene at ROSA26 site | |
CN112029765A (en) | Method for making Metrnl gene conditional knockout mouse model | |
CN111979273A (en) | Method for preparing humanized ACE2 mouse model | |
CN114574526B (en) | Construction method of RPSA gene pig-derived mouse model | |
CN113088521A (en) | Construction method of Ahnak2 gene knockout animal model based on CRISPR/Cas9 technology | |
CN112899311B (en) | Construction method and application of RS1-KO mouse model | |
CN111647623B (en) | Construction method and application of SIRPA humanized animal model | |
CN114457114B (en) | Construction method of animal model for conditional knockout of Fars2 gene | |
CN112626122B (en) | hKDR humanized mouse model and establishing method and application thereof | |
CN109694885B (en) | Method for preparing PI3K gamma whole-body knockout mode mouse based on CRISPR/Cas9 technology, application thereof and kit | |
CN110218743B (en) | Construction method of taurine transporter gene knockout rat model based on CRISPR/Cas9 technology | |
CN110157704B (en) | Mouse for resisting mouse hepatitis virus and preparation method thereof | |
CN114763557A (en) | Application of DDX5 in resisting virus and regulating immune response | |
CN107937439B (en) | Application of gene and construction method of animal model | |
CN116875613B (en) | Construction method and application of humanized H2-D gene knock-in mouse model | |
CN117660527B (en) | Construction method and application of ABCA7-Floxp mouse model | |
CN108048463A (en) | A kind of base sequence, carrier, method and application for building RIP3 knock out mice | |
CN111621500B (en) | Rat model for atrial fibrillation/atrial cardiomyopathy based on MYL4 gene editing and construction method thereof | |
CN117701634A (en) | ITGB5 conditional gene knockout mouse model, construction method and application thereof | |
CN117327697A (en) | Nucleic acid composition of targeted Tekt4 gene, construction method and application of animal model of weak teratospermia | |
CN116790680A (en) | Method for constructing male sterile animal model and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |